ライフサイエンスコーパス: parainfluenza

1 enza B, two respiratory syncytial virus, one parainfluenza).

2 ommon viral infections such as influenza and parainfluenza.

3 onse to a cluster of hospital-acquired human parainfluenza 3 virus (HPIV3) infections at a children's

4 nation respiratory syncytial virus (RSV) and parainfluenza 3 virus (PIV3) live, attenuated intranasal

5 oped antibodies to cytomegalovirus (CMV) and parainfluenza 3.

6 gainst multiple domains of the paramyxovirus parainfluenza 5 (PIV5) pre- and postfusion F and HN.

7 Parainfluenza and coronaviruses were also more common am

8 -derived peptide sequence that inhibits both parainfluenza and Nipah viruses, to investigate the infl

9 Besides influenza A and RSV, influenza B, parainfluenza and norovirus may also contribute substant

10 for influenza, respiratory syncytial virus, parainfluenza, and adenovirus infection.

11 hat fuse at the cell surface, including HIV, parainfluenza, and henipaviruses.

12 95% confidence interval [CI], 1.02-4.69) and parainfluenza-ARI (AOR, 1.86; 95% CI, 1.15-3.01), when c

13 Influenza and parainfluenza ARIs appeared to facilitate pneumococcal a

14 ate an etiologic role, whereas detections of parainfluenza, coronaviruses, rhinovirus, and adenovirus

15 luenza B, respiratory syncytial virus (RSV), parainfluenza, enterovirus, rotavirus, norovirus, Campyl

16 Crystal structures of related parainfluenza F glycoproteins have revealed a large conf

17 quely broad spectrum antiviral activity of a parainfluenza F-derived peptide sequence that inhibits b

18 rhinovirus, respiratory syncytial virus, and parainfluenza has been known for many years.

19 d, particularly in relation to influenza and parainfluenza infections of the respiratory tract.

20 Respiratory syncytial virus, parainfluenza, influenza, and adenovirus accounted for 2

21 Lower-respiratory-tract infection with parainfluenza (odds ratio [OR], 17.9 [95% confidence int

22 flammation and respiratory death after mouse parainfluenza or human influenza virus infection.

23 nts with influenza (A, 11; B, 4) and 24 with parainfluenza (para1, 7; para2, 2; para3, 15).

24 monia was diagnosed in 10 (5 influenza and 5 parainfluenza) patients, and concurrent bacterial pneumo

25 gle-lung 25, double-lung 14) of influenza or parainfluenza respiratory viral infection were identifie

26 Influenza and parainfluenza respiratory viral infections are associate

27 ically important viruses, such as influenza, parainfluenza, respiratory syncytial virus (RSV) and Ebo

28 nd early viral exposure to 3 common viruses (parainfluenza, respiratory syncytial virus, and picornav

29 itis virus, measles, mumps, metapneumovirus, parainfluenza, rotavirus, respiratory syncytial virus, a

30 Similarly, murine parainfluenza (Sendai) respiratory viral infection cause

31 For human parainfluenza type 3 (HPIV3), one bifunctional site on H

32 A phase 2 evaluation of live attenuated parainfluenza type 3 (PIV3)-cold passage mutant 45 (cp45

33 In this study the solution dynamics of human parainfluenza type 3 hemagglutinin-neuraminidase (HN) ha

34 ubjects into respiratory syncytial virus and parainfluenza type 3 vaccine trials when subjects were s

35 A recombinant chimeric bovine/human parainfluenza type 3 virus (rB/HPIV3) vector expressing

36 For human parainfluenza type 3, one bifunctional site on HN can ca

37 Neu5Ac2en derivatives that target the human parainfluenza type-1 hemagglutinin-neuraminidase protein

38 alic acid-based inhibitors that target human parainfluenza type-1 hemagglutinin-neuraminidase.

39 vaccines against viruses such as influenza, parainfluenza types 1-3, measles, dengue, and respirator

40 ke (S) protein from a recombinant attenuated parainfluenza virus (BHPIV3) that is being developed as

41 canine adenovirus type 2 (CAV-2), and canine parainfluenza virus (CPIV), respiratory disease was ende

42 V-respiratory syncytial virus (RSV) or human parainfluenza virus (HPIV) coinfections had wheezing tha

43 The human parainfluenza virus (hPIV) hemagglutinin-neuraminidase (

44 presence of the second binding site on human parainfluenza virus (hPIV) type 1, 2, and 3 and Sendai v

45 es, Respiratory Syncytial Virus (RSV), Human Parainfluenza Virus (HPIV), and Human Metapneumovirus (h

46 (23), human herpesvirus (HHV)-6B (10), human parainfluenza virus (HPIV)-2 (3), HPIV-3 (1), and human

47 for RSV (n = 35), 2.6 x 10(6) copies/mL; for parainfluenza virus (n = 35), 4.9 x 10(7) copies/mL; for

48 rs mutations in the P/V gene from the canine parainfluenza virus (P/V-CPI(-)) is a potent inducer of

49 Respiratory syncytial virus (RSV) and parainfluenza virus (PIV) are two respiratory pathogens

50 Parainfluenza virus (PIV) commonly infects patients foll

51 RSV F and related parainfluenza virus (PIV) F proteins are cleaved by furi

52 Parainfluenza virus (PIV) in humans is associated with b

53 Data on characteristics and outcomes of parainfluenza virus (PIV) infections in these patients a

54 Parainfluenza virus (PIV) is a negative-sense single-str

55 ually and in combinations from a recombinant parainfluenza virus (PIV) type 3 vector called BHPIV3.

56 mens), followed by human rhinovirus (17.8%); parainfluenza virus (PIV) types 1-4 (7.5%); enterovirus

57 sting for respiratory syncytial virus (RSV), parainfluenza virus (PIV), and influenza A and B, and by

58 us (HRV), respiratory syncytial virus (RSV), parainfluenza virus (PIV), influenza virus (InfV), metap

59 (HN, residues 37 to 56) of the paramyxovirus parainfluenza virus (PIV5), a region of the HN stalk tha

60 naturally occurring SV5 variant Wake Forest parainfluenza virus (WF-PIV) activates the synthesis of

61 detects influenza A virus (Flu-A) and Flu-B, parainfluenza virus 1 (PIV-1), PIV-2, and PIV-3, and res

62 l virus (RSV), human metapneumovirus (HMPV), parainfluenza virus 1 to 3 (PIV1, PIV2, and PIV3), and a

63 hese are encoded by mumps virus (MuV), human parainfluenza virus 2 (hPIV2), and parainfluenza virus 5

64 Simian virus 5 (SV5) targets STAT1, human parainfluenza virus 2 targets STAT2, and mumps virus tar

65 ith respiratory syncytial virus (RSV), human parainfluenza virus 3 (HPIV-3), and influenza virus on t

66 We previously reported that a human parainfluenza virus 3 (HPIV3) F peptide effectively inhi

67 titatively influence fusion promotion, human parainfluenza virus 3 (HPIV3) variants with alterations

68 yxoviruses, such as Nipah virus (NiV), human parainfluenza virus 3 (HPIV3), measles virus (MeV), mump

69 Parainfluenza virus 3 (PIV-3) infection is highly restri

70 The majority of this decrease was in parainfluenza virus 3 (PIV3) (8.3% to 2.2%, P < .001).

71 c fibrosis patients; however, its use during parainfluenza virus 3 (PIV3) infection has not been eval

72 The secreted human parainfluenza virus 3 F forms a trimer with distinct hea

73 However, we found that a human parainfluenza virus 3 F-peptide is more effective at inh

74 eaved ectodomain of the paramyxovirus, human parainfluenza virus 3 fusion (F) protein, a member of th

75 homologous HN protein, as well as NDV-human parainfluenza virus 3 HN chimeras.

76 ection but similar to that for influenza and parainfluenza virus 3 infection in all age groups.

77 mumps virus, Newcastle disease virus, human parainfluenza virus 3, and Nipah virus.

78 Antibody titers to RSV, human parainfluenza virus 3, measles, and influenza H1N1, H3N2

79 cell lines with Sendai virus (SeV) or human parainfluenza virus 3, two prototypic paramyxoviruses, c

80 dence similar to that of influenza virus and parainfluenza virus 3.

81 Putative viral pathogens included human parainfluenza virus 4 (aOR 9.3, P = .12), human bocaviru

82 rus [EV], 118; bocavirus, 8; coronavirus, 7; parainfluenza virus 4, 4; Mycoplasma pneumoniae, 1).

83 hat Cav-1 colocalizes with the paramyxovirus parainfluenza virus 5 (PIV-5) nucleocapsid (NP), matrix

84 Parainfluenza virus 5 (PIV5) activates and is neutralize

85 For the paramyxoviruses parainfluenza virus 5 (PIV5) and mumps virus, M-NP inter

86 Proline substitution in this region of HN of parainfluenza virus 5 (PIV5) and Newcastle disease virus

87 In this work, we generated a recombinant parainfluenza virus 5 (PIV5) containing NP from H5N1 (A/

88 The paramyxovirus parainfluenza virus 5 (PIV5) enters cells by fusion of t

89 igh similarity to the structure of prefusion parainfluenza virus 5 (PIV5) F, with the main structural

90 Because only the prefusion structure of the parainfluenza virus 5 (PIV5) F-trimer is available, to s

91 MR spectroscopy, we show that the TMD of the parainfluenza virus 5 (PIV5) fusion protein adopts lipid

92 Parainfluenza virus 5 (PIV5) HN exists as a noncovalent

93 Parainfluenza virus 5 (PIV5) is a member of the Paramyxo

94 Parainfluenza virus 5 (PIV5) is a promising viral vector

95 Parainfluenza virus 5 (PIV5) is a prototypical paramyxov

96 Parainfluenza virus 5 (PIV5) is an appealing vector for

97 Parainfluenza virus 5 (PIV5) is an enveloped, single-str

98 The P protein of parainfluenza virus 5 (PIV5) is an essential cofactor of

99 Parainfluenza virus 5 (PIV5) is thought to contribute to

100 To investigate the role of NP protein in parainfluenza virus 5 (PIV5) particle formation, NP prot

101 In this work, we tested a recombinant parainfluenza virus 5 (PIV5) strain expressing the glyco

102 serendipitously identified a viral mRNA from parainfluenza virus 5 (PIV5) that activates IFN expressi

103 Preparations of parainfluenza virus 5 (PIV5) that are potent activators

104 quence variation of 16 different isolates of parainfluenza virus 5 (PIV5) that were isolated from a n

105 unable to be recognized by measles virus and parainfluenza virus 5 (PIV5) V proteins were tested in s

106 We tested the recombinant parainfluenza virus 5 (PIV5) vectors expressing RSV glyc

107 he threonine residue at position 286 of P of parainfluenza virus 5 (PIV5) was found phosphorylated.

108 The V proteins of measles virus (MV) and parainfluenza virus 5 (PIV5) were introduced into HFLC u

109 rotein (prefusion form) of the paramyxovirus parainfluenza virus 5 (PIV5) WR isolate was determined.

110 Parainfluenza virus 5 (PIV5), a paramyxovirus, is not kn

111 Similar results were also observed with parainfluenza virus 5 (PIV5), a paramyxovirus, when neut

112 Here we show that vaccination with parainfluenza virus 5 (PIV5), a promising live viral vec

113 Infection by parainfluenza virus 5 (PIV5), a prototypical member of t

114 Parainfluenza virus 5 (PIV5), a prototypical paramyxovir

115 The genome of parainfluenza virus 5 (PIV5), a prototypical paramyxovir

116 V), human parainfluenza virus 2 (hPIV2), and parainfluenza virus 5 (PIV5), all members of the genus R

117 Parainfluenza virus 5 (PIV5), formerly known as simian v

118 that a porcine isolate of the paramyxovirus parainfluenza virus 5 (PIV5), known as SER, requires a l

119 The strain diversity of a rubulavirus, parainfluenza virus 5 (PIV5), was investigated by compar

120 Previously, we developed two parainfluenza virus 5 (PIV5)-based RSV vaccine candidate

121 We previously generated a parainfluenza virus 5 (PIV5)-vectored vaccine candidate

122 In this study, we evaluated two parainfluenza virus 5 (PIV5)-vectored vaccines expressin

123 he FP of the F protein of the paramyxovirus, parainfluenza virus 5 (PIV5).

124 f the matrix (M) protein of a paramyxovirus, parainfluenza virus 5 (PIV5).

125 -3 as a binding partner for the M protein of parainfluenza virus 5 (PIV5).

126 Similar results were also observed with parainfluenza virus 5 (PIV5).

127 on (F) protein from the paramyxovirus simian parainfluenza virus 5 (SV5) resulted in mutant F protein

128 NASEK was dispensable for viruses, including parainfluenza virus 5 and Coxsackie B virus, that enter

129 ructed chimeras containing the ectodomain of parainfluenza virus 5 F (PIV5 F) and either the MPER, th

130 Here we report the crystal structure of the parainfluenza virus 5 F protein in its prefusion conform

131 ess the functional role of the paramyxovirus parainfluenza virus 5 F protein TM domain, alanine scann

132 Here, a soluble form of parainfluenza virus 5 F was triggered to refold using te

133 , we show that the FP from the paramyxovirus parainfluenza virus 5 fusogenic protein, F, forms an N-t

134 ng globular head domain of the paramyxovirus parainfluenza virus 5 HN protein is entirely dispensable

135 usion activation, F activation involving the parainfluenza virus 5 HN stalk domain, and properties of

136 By modeling the crystal structure of parainfluenza virus 5 into the density, it is shown that

137 The paramyxovirus parainfluenza virus 5 mediates membrane merger through i

138 t robust maturation following infection with parainfluenza virus 5 or influenza virus.

139 this study, we show that vaccination with a parainfluenza virus 5 recombinant vaccine candidate expr

140 ed "stalk exposure model" first proposed for parainfluenza virus 5 to other paramyxoviruses and propo

141 athogens: human respiratory syncytial virus, parainfluenza virus 5, and Sendai virus.

142 A parainfluenza virus 5-vectored vaccine expressing the na

143 sequence, FPIV, important for the budding of parainfluenza virus 5.

144 recently published prefusogenic structure of parainfluenza virus 5/SV5 F places CBF(2) in direct cont

145 or detecting respiratory viruses, especially parainfluenza virus and adenovirus.

146 d five in which the PLx-RVP failed to detect parainfluenza virus and one in which the detection of in

147 ow fever virus, Japanese encephalitis virus, parainfluenza virus and Sendai virus.

148 sociation with age; especially rhinovirus or parainfluenza virus detection showed positive associatio

149 While type II human parainfluenza virus induces STAT2 degradation, simian vi

150 Analysis of parainfluenza virus infection in mice revealed an unexpe

151 We used mouse models of influenza and parainfluenza virus infection to show that intranasally

152 uenza virus, respiratory syncytial virus, or parainfluenza virus infection.

153 in mixed bone marrow chimeric mice during a parainfluenza virus infection.

154 central memory subpopulations to intranasal parainfluenza virus infection.

155 ccine nor clinically effective treatment for parainfluenza virus infection.

156 Parainfluenza virus infections did not differentially af

157 to pneumonitis and/or mortality of treating parainfluenza virus infections with available (ribavirin

158 ools elicited by nonpersistent influenza and parainfluenza virus infections.

159 iratory syncytial virus, 2 adenovirus, and 1 parainfluenza virus infections.

160 mouse model in which infection with a mouse parainfluenza virus known as Sendai virus (SeV) leads to

161 significance of membrane fusion activity in parainfluenza virus replication and pathogenesis in vivo

162 e (HN) glycoprotein plays a critical role in parainfluenza virus replication.

163 The parainfluenza virus simian virus 5 (SV5) is a poor induc

164 Human epithelial cells infected with the parainfluenza virus simian virus 5 (SV5) show minimal ac

165 aring the sequence of MV F with those of the parainfluenza virus SV5 and Newcastle disease virus (NDV

166 SER virus is a type 5 parainfluenza virus that does not exhibit syncytium form

167 eviously described heterotypic peptides from parainfluenza virus that potently inhibit Nipah virus in

168 e protein or whole virus digests enables the parainfluenza virus to be identified and typed and for i

169 ontact transmission, the predominant mode of parainfluenza virus transmission, was modeled accurately

170 n to the catalytic binding site, HN of human parainfluenza virus type 1 (hPIV-1) may have a second re

171 Human parainfluenza virus type 1 (HPIV1) also causes severe pe

172 Sendai virus (SeV) and human parainfluenza virus type 1 (hPIV1) are highly similar in

173 We evaluated a version of human parainfluenza virus type 1 (HPIV1) bearing a stabilized

174 Sendai virus (SV) and human parainfluenza virus type 1 (hPIV1) have genomes consisti

175 Human parainfluenza virus type 1 (HPIV1) is a significant caus

176 Human parainfluenza virus type 1 (HPIV1) is a significant caus

177 Human parainfluenza virus type 1 (HPIV1) is an important respi

178 Human parainfluenza virus type 1 (HPIV1) is an important respi

179 respiratory syncytial virus (RSV) and human parainfluenza virus type 1 (HPIV1) to HPIV4 infect virtu

180 onkeys from challenge with the related human parainfluenza virus type 1 (hPIV1), and SV has advanced

181 valuation of an attenuated recombinant human parainfluenza virus type 1 (rHPIV1) expressing the membr

182 Live attenuated recombinant human parainfluenza virus type 1 (rHPIV1) was investigated as

183 Recombinant human parainfluenza virus type 1 (rHPIV1) was modified to crea

184 ons of the L polymerase of recombinant human parainfluenza virus type 1 (rHPIV1).

185 live virus vaccine, we have used the murine parainfluenza virus type 1 (Sendai virus [SV]) as a xeno

186 Hamsters immunized with a recombinant human parainfluenza virus type 1 expressing the fusion F prote

187 Human parainfluenza virus type 1 is the major cause of croup i

188 secreted from A549 cells infected with Human parainfluenza virus type 2 (HPIV-2) but not from cells i

189 Human parainfluenza virus type 2 (HPIV-2), an important pediat

190 Human parainfluenza virus type 2 (HPIV2) is the only member of

191 t for association with V proteins from human parainfluenza virus type 2, parainfluenza virus type 5,

192 The Kansas strain of bovine parainfluenza virus type 3 (BPIV3) is 100- to 1,000-fold

193 doses of an intranasal vaccine using bovine parainfluenza virus type 3 (bPIV3).

194 Entry and fusion of human parainfluenza virus type 3 (HPF3) require the interactio

195 ur previous observation on the role of human parainfluenza virus type 3 (HPIV 3) C protein in the tra

196 The RNA polymerase complex of human parainfluenza virus type 3 (HPIV 3), a member of the fam

197 Human parainfluenza virus type 3 (hPIV-3) is a clinically sign

198 Human parainfluenza virus type 3 (HPIV-3) is an airborne patho

199 valent live attenuated vaccine against human parainfluenza virus type 3 (HPIV3) and respiratory syncy

200 respiratory syncytial virus (RSV) and human parainfluenza virus type 3 (HPIV3) are major pediatric r

201 respiratory syncytial virus (RSV) and human parainfluenza virus type 3 (HPIV3) are major viral agent

202 SV), human metapneumovirus (hMPV), and human parainfluenza virus type 3 (hPIV3) are responsible for t

203 Respiratory syncytial virus (RSV) and human parainfluenza virus type 3 (HPIV3) are the first and sec

204 Respiratory syncytial virus (RSV) and human parainfluenza virus type 3 (HPIV3) are two major causes

205 The genomic promoter of human parainfluenza virus type 3 (HPIV3) contains multiple cis

206 genes, of a gene cassette encoding the human parainfluenza virus type 3 (HPIV3) hemagglutinin-neurami

207 t also the receptor interaction of the human parainfluenza virus type 3 (HPIV3) hemagglutinin-neurami

208 plementation to follow the dynamics of human parainfluenza virus type 3 (HPIV3) HN/F pairs in living

209 We demonstrate that human parainfluenza virus type 3 (HPIV3) induces incomplete au

210 onnected to the stalk region of either human parainfluenza virus type 3 (HPIV3) or Nipah virus recept

211 against Ebola virus (EV), recombinant human parainfluenza virus type 3 (HPIV3) was modified to expre

212 rt here that for three paramyxoviruses-human parainfluenza virus type 3 (HPIV3), a major cause of low

213 Human parainfluenza virus type 3 (HPIV3), a paramyxovirus, is

214 common pediatric respiratory pathogen, human parainfluenza virus type 3 (HPIV3), as a vaccine vector

215 encephalomyocarditis virus (EMCV) and human parainfluenza virus type 3 (HPIV3), induced down-regulat

216 ing the childhood respiratory pathogen human parainfluenza virus type 3 (HPIV3), possess an envelope

217 For human parainfluenza virus type 3 (HPIV3), the effects of speci

218 For human parainfluenza virus type 3 (HPIV3), the receptor binding

219 aminidase (HN) surface glycoprotein of human parainfluenza virus type 3 (HPIV3).

220 intranasal paediatric vaccine against human parainfluenza virus type 3 (HPIV3).

221 s), Newcastle disease virus (NDV), and human parainfluenza virus type 3 (HPIV3).

222 In this study, a chimeric bovine/human (b/h) parainfluenza virus type 3 (PIV3) expressing the human P

223 Parainfluenza virus type 3 (PIV3) infection led to laryn

224 Parainfluenza virus type 3 (PIV3) infections are a major

225 Parainfluenza virus type 3 (PIV3) is major pathogen of c

226 r the ability to inhibit the growth of human parainfluenza virus type 3 (PIV3), a nonsegmented negati

227 A live attenuated bovine parainfluenza virus type 3 (PIV3), harboring the fusion

228 A live attenuated chimeric bovine/human parainfluenza virus type 3 (rB/HPIV3) was developed prev

229 We constructed a human recombinant parainfluenza virus type 3 (rPIV3) that expresses enhanc

230 For human parainfluenza virus type 3 and many other paramyxoviruse

231 tial innate antiviral response against human parainfluenza virus type 3 and respiratory syncytial vir

232 s virus of the Arenaviridae family and human parainfluenza virus type 3 of the Paramyxoviridae family

233 Human parainfluenza virus type 3, a mildly cytopathic virus th

234 yncytial virus, human metapneumovirus, human parainfluenza virus type 3, and measles virus, and highl

235 uses, including the childhood pathogen human parainfluenza virus type 3, enter host cells by fusion o

236 explores the binding and entry into cells of parainfluenza virus type 3, focusing on how the receptor

237 minidase abolished infection of HAE by human parainfluenza virus type 3, this treatment did not signi

238 vaccine for respiratory syncytial virus and parainfluenza virus type 3, two major causes of severe r

239 viruses, including the human pathogen human parainfluenza virus type 3, yet these compounds by thems

240 protective efficacy of an aerosolized human parainfluenza virus type 3-vectored vaccine that express

241 lymphocytic choriomeningitis virus and human parainfluenza virus type 3.

242 ction of interferon (IFN) alpha/beta against parainfluenza virus type 5 (PIV5), selectively inhibitin

243 teins from human parainfluenza virus type 2, parainfluenza virus type 5, measles virus, mumps virus,

244 We investigated the binding of human parainfluenza virus types 1 and 3 (hPIV1 and hPIV3, resp

245 luding influenza virus A, influenza virus B, parainfluenza virus types 1 and 3, respiratory syncytial

246 A and B and human metapneumovirus, and (iii) parainfluenza virus types 1 to 4.

247 virus (RSV), influenza virus type A (FluA), parainfluenza virus types 1, 2, and 3 (PIV1, PIV2, and P

248 iratory syncytial viruses A and B; and human parainfluenza virus types 1, 2, and 3.

249 iruses, including influenza A and B viruses, parainfluenza virus types 1-3, respiratory syncytial vir

250 act of respiratory syncytial virus (RSV) and parainfluenza virus URIs on the frequency of AOM caused

251 C28a HN is the first parainfluenza virus variant found so far to be specifica

252 ple viruses (respiratory syncytial virus and parainfluenza virus) and multiple phenotypes.

253 infected cells (Wake Forest strain of Canine parainfluenza virus) induced IL-8 secretion by a mechani

254 pproach is further demonstrated here for the parainfluenza virus, a virus which can be life threateni

255 tory syncytial virus, human metapneumovirus, parainfluenza virus, and influenza virus) by reverse-tra

256 ents with respiratory syncytial virus (RSV), parainfluenza virus, influenza virus, metapneumovirus (M

257 roviruses, influenza virus, metapneumovirus, parainfluenza virus, rhinovirus, and respiratory syncyti

258 so showed that extraction will be needed for parainfluenza virus, which was only identified correctly

259 tudies we tested the role of CD8+ T cells in parainfluenza virus-induced hyperreactivity and M2R dysf

260 rus, rhinovirus, and influenza virus but not parainfluenza virus.

261 t for lower-respiratory-tract infection with parainfluenza virus; it stabilized during the months aft

262 he hemagglutinin-neuraminidase (HN) of human parainfluenza viruses (hPIV) in vitro and protected mice

263 Human parainfluenza viruses (HPIVs) are a common cause of acut

264 Human parainfluenza viruses (HPIVs) are among the most common

265 glutinin-neuraminidase (HN) protein of human parainfluenza viruses (hPIVs) both binds (H) and cleaves

266 Human parainfluenza viruses (HPIVs) cause widespread respirato

267 The first step in infection by human parainfluenza viruses (HPIVs) is binding to the surface

268 The paramyxoviruses, including human parainfluenza viruses (HPIVs), cause a large share of th

269 Parainfluenza viruses (PIVs) are one of the most common

270 ed negative for respiratory syncytial virus, parainfluenza viruses (types 1-3), influenza A and B vir

271 FilmArray RP detected more parainfluenza viruses 1 and 3 than ProParaflu+ (18 versu

272 virus, influenza A virus, influenza B virus, parainfluenza viruses 1 to 3, and respiratory syncytial

273 nfluenza A virus H1-2009, influenza B virus, parainfluenza viruses 1 to 4, respiratory syncytial viru

274 syncytial virus; influenza A and B viruses; parainfluenza viruses 1, 2, 3, and 4; human metapneumovi

275 an respiratory syncytial virus (HRSV); human parainfluenza viruses 1, 2, and 3 (HPIV1, -2, and -3, re

276 piratory syncytial virus, influenza A and B, parainfluenza viruses 1-3, and adenovirus.

277 picornaviruses, coronaviruses 229E and OC43, parainfluenza viruses 1-3, influenza viruses AH1, AH3, a

278 in reaction for respiratory syncytial virus, parainfluenza viruses 1-4, influenza A and B, human meta

279 lture (metapneumovirus, coronaviruses [CoV], parainfluenza viruses 4a and 4b, and rhinoviruses) and t

280 Parainfluenza viruses are a common cause of seasonal res

281 Parainfluenza viruses are known to inhibit type I interf

282 protein and nucleocapsid sustain assembly of parainfluenza viruses at the plasma membrane.

283 Three human parainfluenza viruses bind to glycans terminating with N

284 (RSV), adenoviruses, influenza viruses, and parainfluenza viruses by use of nested polymerase chain

285 Human parainfluenza viruses cause several serious respiratory

286 Although influenza and parainfluenza viruses commonly cause respiratory tract i

287 Our results illustrate how the particles of parainfluenza viruses efficiently accommodate cargoes of

288 Parainfluenza viruses enter host cells by fusing the vir

289 Parainfluenza viruses initiate infection by binding to c

290 Paramyxoviruses such as human parainfluenza viruses that bear inserts encoding protect

291 ew evidence regarding strategies employed by parainfluenza viruses to effectively circumvent respirat

292 on of 274 of 279 influenza viruses, 33 of 38 parainfluenza viruses, 35 of 51 adenoviruses, and 52 of

293 etapneumovirus, respiratory syncytial virus, parainfluenza viruses, and Haemophilus influenzae being

294 causes of lower respiratory disease like the parainfluenza viruses, as well as agents of lethal encep

295 , which include respiratory syncytial virus, parainfluenza viruses, coronavirus, rhinovirus, and huma

296 ruses, including measles virus, mumps virus, parainfluenza viruses, respiratory syncytial virus, huma

297 p of viruses that includes measles virus and parainfluenza viruses.

298 an respiratory syncytial virus and the human parainfluenza viruses.

299 tein subunits play the cell entry concert of parainfluenza viruses.

300 y in all studied age groups; influenza B and parainfluenza were additionally associated in those aged